New drug classes for the treatment of partial onset epilepsy: Focus on perampanel

Jerry J. Shih, William O. Tatum, Leslie A. Rudzinski

Research output: Contribution to journalReview article

12 Scopus citations

Abstract

Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca2+ and selectively blocks AMPA receptor-mediated synaptic trans-mission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June-September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties.

Original languageEnglish (US)
Pages (from-to)285-293
Number of pages9
JournalTherapeutics and Clinical Risk Management
Volume9
Issue number1
DOIs
StatePublished - 2013

Keywords

  • Efficacy
  • Mechanism of action
  • Perampanel
  • Review

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Fingerprint Dive into the research topics of 'New drug classes for the treatment of partial onset epilepsy: Focus on perampanel'. Together they form a unique fingerprint.

  • Cite this